EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials

Judith Hsia iD, Alex C Spyropoulos iD, Gregory Piazza, Stephen Weng, Michael W Dunne, Concetta Lipardi, Elliot S Barnathan iD, Marc P Bonaca

Thrombosis and Haemostasis · 01.07.2024 · 124 (07) · 649-655

DOI: 10.1055/a-2216-5848 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.07.2024. Verfasst von Judith Hsia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Colorado Prevention Center and Department of Medicine, University of Colorado, Aurora, Colorado, United States. Hauptthemen laut MEDLINE: Rivaroxaban, COVID-19, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gates Philanthropy Partnerships and the Bill and Melinda Gates Foundation, Janssen Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We conducted a prespecified meta-analysis of two randomized, placebo-controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute coronavirus disease 2019 (COVID-19). Individually, the trials had limited power to detect a treatment effect due to recruitment stopping ahead of plan. Material and Methods The statistical analysis plan for the meta-analysis was finalized before unblinding of PREVENT-HD, the larger of the two trials. Pooled risk ratios and pooled risk differences along with the two-sided 95% confidence intervals were calculated using random-effect models.

Results

Rivaroxaban did not reduce the occurrence of either the primary prespecified endpoint, a composite of symptomatic arterial and venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, all-cause hospitalization, and all-cause mortality (risk difference: 0.0044; 95% confidence interval: −0.0263, 0.0175; p = 0.69 for pooled risk difference) or the secondary endpoint of all-cause hospitalization (p = 0.76). Although thrombotic events were infrequent, pooled analysis did reveal that rivaroxaban reduced arterial and venous thrombotic events (placebo 6 events, rivaroxaban 0 events; pooled risk difference: −0.0068; 95% confidence interval: −0.0132, −0.0006; p = 0.03). In the pooled studies, only one major bleeding event was observed in a rivaroxaban-allocated patient with no critical site or fatal bleeding events.

Conclusion

Although this meta-analysis does not support antithrombotic prophylaxis with rivaroxaban in a broad prehospital population with acute COVID-19, the prevention of arterial and venous thrombotic events among rivaroxaban-allocated patients is consistent with the known thromboprophylactic effect of the drug in medically ill patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanCOVID-19Randomized Controlled Trials as TopicHumansFactor Xa InhibitorsSARS-CoV-2HemorrhageCOVID-19 Drug TreatmentHospitalizationThrombosisMaleFemaleMiddle AgedFibrinolytic AgentsTreatment OutcomeAged

Substanzen

RivaroxabanFactor Xa InhibitorsFibrinolytic Agents

Autor:innen und Institutionen

  • Colorado Prevention Center and Department of Medicine, University of Colorado, Aurora, Colorado, United States.
  • Feinstein Institutes for Medical Research and Department of Medicine, Northwell Health, New York, New York, United States.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.
  • Janssen Research and Development, Statistical Decision Sciences, Cardiovascular and Metabolism, High Wycombe, United Kingdom.
  • Bill and Melinda Gates Medical Research Institute, Cambridge, Massachusetts, United States.
  • Janssen Research and Development, Clinical Development, Raritan, New Jersey, United States.

ORCID-Profile: Judith Hsia, Alex C Spyropoulos, Elliot S Barnathan

Förderung

  • Gates Philanthropy Partnerships and the Bill and Melinda Gates Foundation
  • Janssen Pharmaceuticals

Zitieren

APA

Hsia, J., Spyropoulos, A. C., Piazza, G., Weng, S., Dunne, M. W., Lipardi, C., Barnathan, E. S., & Bonaca, M. P. (2024). Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thrombosis and Haemostasis, 124(07), 649-655. https://doi.org/10.1055/a-2216-5848

Vancouver

Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, et al. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thrombosis and Haemostasis. 2024;124(07):649-655. doi:10.1055/a-2216-5848

BibTeX
@article{Hsia2024,
  author = {Hsia, Judith and Spyropoulos, Alex C and Piazza, Gregory and Weng, Stephen and Dunne, Michael W and Lipardi, Concetta and Barnathan, Elliot S and Bonaca, Marc P},
  title = {Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {07},
  pages = {649--655},
  doi = {10.1055/a-2216-5848}
}
Kostenlos starten →